Retifanlimab

Cat. No.: HY-P99941 Purity: 96.84%: Data Sheet
SDS

COA
Technical Support

Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA).

For research use only. We do not sell to patients.

CAS No. : 2079108-44-2

Size	Price	Stock	Quantity
1 mg	USD 300	In-stock	Estimated Time of Arrival: April 10
5 mg	USD 780	In-stock	Estimated Time of Arrival: April 10
10 mg	USD 1250	In-stock	Estimated Time of Arrival: April 10
50 mg		Get quote
100 mg		Get quote

Get it by tomorrow April 10 for select sizes. Order within 3 hrs 9 mins.

or Bulk Inquiry

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Retifanlimab Featured Recommendations:

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA)^[1].

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species

Chimeric; Humanized

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02393248	Incyte Corporation	Lung Cancer\|Solid Tumor\|Gastric Cancer\|Urothelial Cancer\|Endometrial Cancer\|Multiple Myeloma\|Myeloproliferative Neoplasms\|Breast Cancer\|Cholangiocarcinoma\|UC\|MPN	February 27, 2015	Phase 1\|Phase 2
NCT05359692	Incyte Biosciences International Sàrl\|Incyte Corporation	Recurrent Cancer\|Metastatic Cancer\|Advanced Malignancies\|Head and Neck Squamous Cell Carcinoma	March 1, 2023	Phase 2
NCT03328026	BriaCell Therapeutics Corporation\|LumaBridge	Breast Cancer\|Breast Neoplasm\|Metastatic Breast Cancer\|Breast Cancer Metastatic	March 16, 2018	Phase 1\|Phase 2
NCT04776876	M.D. Anderson Cancer Center	Advanced Neuroendocrine Neoplasm\|Carcinoid Syndrome	March 1, 2021	Phase 2
NCT05455697	University of Washington	Diffuse Large B-Cell Lymphoma\|Grade 3b Follicular Lymphoma\|High Grade B-Cell Lymphoma	January 26, 2023	Phase 1\|Phase 2
NCT04082364	MacroGenics\|Zai Lab (Shanghai) Co., Ltd.	Gastric Cancer\|Gastroesophageal Junction Cancer\|HER2-positive Gastric Cancer	September 30, 2019	Phase 2\|Phase 3
NCT05440942	Peter Hosein, MD\|Incyte Corporation\|Novartis Pharmaceuticals\|University of Miami Sylvester Comprehensive Cancer Center\|University of Miami	Pancreatic Ductal Adenocarcinoma	January 19, 2023	Phase 1
NCT05743595	Washington University School of Medicine\|Incyte Corporation\|Ichor Medical Systems Incorporated	Unmethylated Glioblastoma	October 31, 2023	Phase 1
NCT04203511	Incyte Corporation	Non-small Cell Lung Cancer	July 31, 2020	Phase 3
NCT03597295	Incyte Corporation	Squamous Cell Carcinoma of Anal Canal	October 8, 2018	Phase 2
NCT04463771	Incyte Corporation\|GOG Foundation\|European Network of Gynaecological Oncological Trial Groups (ENGOT)	Endometrial Cancer	January 26, 2021	Phase 2
NCT03406949	MacroGenics	Advanced Solid Tumors	February 27, 2018	Phase 1
NCT04634825	MacroGenics	Head and Neck Cancer\|Head and Neck Neoplasms\|Head and Neck Squamous Cell Carcinoma	March 17, 2021	Phase 2
NCT03920839	Incyte Corporation	Advanced and+or Metastatic Solid Tumors\|Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer\|Advanced+Metastatic Unresectable Malignant Pleural Mesothelioma	July 15, 2019	Phase 1
NCT04205812	Incyte Corporation\|Zai Lab (Shanghai) Co., Ltd.	Metastatic Squamous Non-Small Cell Lung Cancer\|Metastatic Nonsquamous Non-Small Cell Lung Cancer	September 27, 2020	Phase 3
NCT03589651	Incyte Corporation	Unresectable or Metastatic Solid Tumors	August 17, 2018	Phase 1
NCT05083754	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Incyte Corporation	Glioblastoma Multiforme	August 31, 2022	Phase 1
NCT03599713	Incyte Corporation	Metastatic Merkel Cell Carcinoma	February 25, 2019	Phase 2
NCT03679767	Incyte Corporation	Metastatic Non-small Cell Lung Cancer\|Locally Advanced Urothelial Cancer\|Metastatic Urothelial Cancer\|Unresectable Melanoma\|Metastatic Melanoma\|Locally Advanced Renal Cell Carcinoma\|Metastatic Clear-Cell Renal Cell Carcinoma	January 9, 2019	Phase 2
NCT05177133	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)\|Incyte Corporation	Gastric Adenocarcinoma\|Esophageal Adenocarcinoma	November 5, 2021	Phase 2
NCT03532295	Washington University School of Medicine\|Incyte Corporation	Glioma\|Glioblastoma	April 20, 2020	Phase 2
NCT04472429	Incyte Corporation	Squamous Cell Carcinoma of the Anal Canal	January 12, 2021	Phase 3
NCT04989387	Incyte Corporation	Advanced Solid Tumors\|Squamous Cell Carcinoma of the Head and Neck (SCCHN)\|Gastrointestinal (GI) Malignancies	October 4, 2021	Phase 1
NCT03729596	MacroGenics	Squamous Cell Carcinoma of Head and Neck\|Triple Negative Breast Cancer\|Melanoma\|Advanced Solid Tumor, Adult\|Metastatic Castrate Resistant Prostate Cancer\|Non Small Cell Lung Cancer	November 21, 2018	Phase 1\|Phase 2
NCT04577014	Memorial Sloan Kettering Cancer Center\|Incyte Corporation	Soft Tissue Sarcoma\|Sarcoma,Soft Tissue\|Sarcoma\|Soft Tissue Sarcoma Adult	September 29, 2020	Phase 1\|Phase 2
NCT05239182	Anwaar Saeed\|Actuate Therapeutics Inc.\|Incyte Corporation\|University of Pittsburgh	Pancreatic Adenocarcinoma	January 26, 2022	Phase 2
NCT04586244	Incyte Corporation	Urothelial Carcinoma	January 14, 2022	Phase 2
NCT05594290	Gruppo Oncologico del Nord-Ovest	Merkel Cell Carcinoma	December 7, 2022	Phase 2
NCT03910530	Incyte Biosciences Japan GK\|Incyte Corporation	Advanced Solid Tumors\|Metastatic Solid Tumors	July 22, 2019	Phase 1
NCT04949191	Incyte Corporation	Advanced Malignancies	July 12, 2021	Phase 2
NCT04445844	Rutgers, The State University of New Jersey\|Incyte Corporation\|Oncolytics Biotech\|National Cancer Institute (NCI)	Anatomic Stage IV Breast Cancer AJCC v8\|Locally Advanced Breast Carcinoma\|Metastatic Triple-Negative Breast Carcinoma\|Prognostic Stage IV Breast Cancer AJCC v8\|Triple-negative Breast Cancer	July 13, 2020	Phase 2
NCT03059823	Incyte Corporation	Locally Advanced Solid Tumors\|Metastatic Solid Tumors	November 15, 2016	Phase 1
NCT05287113	Incyte Biosciences International Sàrl\|Incyte Corporation	Head and Neck Cancer	November 14, 2022	Phase 2
NCT05345002	Stephen Bagley, MD, MSCE\|Incyte Corporation\|University of Pennsylvania	Glioma\|IDH Mutation\|Astrocytoma\|Oligodendroglioma	November 16, 2022	Phase 2
NCT04799431	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Incyte Corporation\|National Cancer Institute (NCI)	Pancreatic Cancer Metastatic\|Colorectal Cancer Metastatic	May 3, 2023	Phase 1

CAS No.

2079108-44-2

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Retifanlimab]

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Format

Human IgG4 kappa

Biological Activity

Immobilized Human PD-1 Protein (ECD, His Tag) can bind Retifanlimab. The EC₅₀ for this effect is 3.71 ng/mL.

Purity & Documentation

Purity: 96.84%

Select Batch:

Data Sheet (255 KB) SDS (251 KB)

COA (232 KB)SDS-PAGE (89 KB)SEC-HPLC (133 KB)

Inhibitory Antibodies User Guide (602 KB)

References

[1]. D V T Catenacci, et al. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A. ESMO Open. 2022 Oct;7(5):100563. [Content Brief]

Retifanlimab Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Keywords:

Retifanlimab2079108-44-2PD-1/PD-L1PD-1/Programmed death-ligand 1Human epidermal growth factor receptor 2 (HER2)anti-programmed cell death protein 1 (anti-PD-1)monoclonal antibody (mAb)gastroesophageal adenocarcinoma (GEA)Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Retifanlimab

Customer Review

Retifanlimab Featured Recommendations:

Retifanlimab Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

Biological Activity

Purity & Documentation

References

Customer Review

Retifanlimab Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report